Skip to content

cobas CMV Test

by Roche Molecular Systems, Inc.

PMA P160041510(k) K252481

Active United States

PMA 510(k)

Valid until

No expiry

FDA authorization is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Source FDA 510(k), FDA PMA, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE 510(k) Substantially Equivalent · Traditional NumberK252481 Date3 Nov 2025ClearedStatusActive
United StatesFDA PMA PMA NumberP160041 Date1 Jun 2017ApprovedStatusActive

Official records

From the FDA record

FDA PMA P160041

Received by the FDA
7 Aug 2025
FDA decision
3 Nov 2025 (Substantially Equivalent)
FDA review time
88 days from receipt to decision
Docket number
17M-3430
Approval order statement, verbatim
Approval of the cobas CMV test - This device is indicated for:cobas® CMV is an in vitro nucleic acid amplification test for the quantitation of cytomegalovirus (CMV) DNA in human EDTA plasma. cobas® CMV is intended for use as an aid in the management of CMV in solid organ transplant patients and in hematopoietic stem cell transplant patients. In patients receiving anti-CMV therapy, serial DNA measurements can be used to assess viral response to treatment. The results from cobas® CMV must be interpreted within the context of all relevant clinical and laboratory findings. cobas® CMV is not intended for use as a screening test for blood or blood products.

From the FDA PMA record P160041 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Across registries

2 registries list this device

  • FDA 510(k) K252481 decided 3 Nov 2025 Active
  • FDA PMA P160041 decided 1 Jun 2017 Active

Timeline

2 dated events

  1. Approved FDA PMA P160041
  2. Cleared FDA 510(k) K252481

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k), FDA PMA Active

Specification

510(k) · PMA

Trade name
Cobas Cmv
Generic name
Cytomegalovirus (cmv) dna quantitative assay
PMA number
510(k) Number
FDA product code
PAB
Device class
Class II
Regulation
21 CFR Part 866.3180
Advisory committee
Microbiology
FDA decision
SESE Substantially Equivalent

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The cobas CMV Test is an in vitro nucleic acid amplification assay for the quantitative detection of cytomegalovirus (CMV) DNA in human EDTA plasma. Classified as a microbiology device under the FDA’s nomenclature, it provides measurable viral load results to aid in clinical decision-making for CMV management.

This test is intended for use in solid organ and hematopoietic stem cell transplant patients to monitor CMV infection and assess response to anti-CMV therapy. Supplied as a single-use reagent kit, it requires laboratory processing and is not approved for blood screening. Authorized under FDA 510(k) clearance (K252481) and PMA (P160041), compliance with regulatory standards ensures accurate quantitation of CMV DNA for clinical management.

Similar devices

Other devices filed under FDA product code PAB (Cytomegalovirus (Cmv) Dna Quantitative Assay).

Other devices from Roche Molecular System, Inc.

See all devices from Roche Molecular System, Inc. →